Durable Remissions in CLL With Fixed-Duration ... - CLL Support
Durable Remissions in CLL With Fixed-Duration Triplet (Gazyva, Imbruvica, Venclexta) at 4 Years
You need to be a member of this community to see this post.
Read more about...
11 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL....
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
GAZYVA® (Obinutuzumab) gains TGA approval for 1st line treatment of CLL in combination with Chlorambucil in Australia
GAZYVA, a new anti-CD20 monoclonal antibody, is now Therapeutic Goods Administration (TGA)...
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jan 19,...
Related Posts
- Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
- Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
- Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada
- Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
